NYLIM
MYGN icon

New York Life Investment Management’s Myriad Genetics MYGN Stock Holding History

New York Life Investment Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-22,508
Closed -$327K – 1320
2022
Q4 		$327K Buy
22,508
+2,535
+13% +$47.2K ﹤0.01% 1107
2022
Q3 		$381K Buy
19,973
+1,467
+8% +$33.7K ﹤0.01% 983
2022
Q2 		$336K Buy
+18,506
New +$384K ﹤0.01% 1107

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

New York Life Investment Management's MYGN Position: Q1 2023 in Review

New York Life Investment Management sold out of Myriad Genetics (MYGN) in Q1 2023, closing a stake of 22,508 shares — an estimated $327K sold.

New York Life Investment Management first reported a position in MYGN in Q2 2022 and held it in 3 quarters. The position peaked at $381K in Q3 2022. 190 funds tracked by Wall St. Rank hold MYGN as of Q1 2023.

  • New York Life Investment Management reported no remaining Myriad Genetics position as of Q1 2023 after selling out during the quarter.
  • New York Life Investment Management sold 22,508 Myriad Genetics shares in Q1 2023, an estimated $327K.
  • New York Life Investment Management first reported a position in Myriad Genetics in Q2 2022 and held it in 3 quarters.
  • New York Life Investment Management's Myriad Genetics position peaked at $381K in Q3 2022.
  • 190 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2023.

Based on New York Life Investment Management's 13F filing for Q1 2023, filed 8 May 2023.